Skip to content

Development Plan for Evorpacept

We are pursuing a robust development plan for evorpacept across a breadth of indications in solid and hematologic cancers with multiple combination partners.

Modality/
Target 		Program Indication
Phase
Evorpacept Programs
Anti-cancer Antibodies
ASPEN-Breast
Evorpacept, Trastuzumab + chemotherapy
ENHERTU®-Experienced HER2-Positive Breast Cancer
mid phase 2
SARCLISA® + Dexamethasone¹ + Evorpacept
RRMM (Relapsed or Refractory Multiple Myeloma)
mid phase 1
ASPEN-06
Evorpacept, Trastuzumab, CYRAMZA® + Paclitaxel²
2L or 3L Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction (GEJ)
mid phase 2
Zanidatamab³ + Evorpacept
HER2-Expressing Breast Cancer and Other Cancers
mid phase 2
ALX2004 Program
EGFR ADC
ALX2004
Dose-escalation and expansion
EGFR-Expressing Solid Tumors
mid phase 1

Evorpacept Programs

ASPEN-Breast
Evorpacept, Trastuzumab + chemotherapy
Modality/Target
Anti-cancer Antibodies
Indication
ENHERTU®-Experienced HER2-Positive Breast Cancer
Status
FPI mid-year ’25
mid phase 2
SARCLISA® + Dexamethasone¹ + Evorpacept
Modality/Target
Anti-cancer Antibodies
Indication
RRMM (Relapsed or Refractory Multiple Myeloma)
Status
FPI Q3 ‘24, Currently Enrolling
mid phase 1
ASPEN-06
Evorpacept, Trastuzumab, CYRAMZA® + Paclitaxel²
Modality/Target
Anti-cancer Antibodies
Indication
2L or 3L Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction (GEJ)
Status
Completed, established POC, seeking partner ex-US
mid phase 2
Zanidatamab³ + Evorpacept
Modality/Target
Anti-cancer Antibodies
Indication
HER2-Expressing Breast Cancer and Other Cancers
Status
Completed, data presented at SABCS ‘24
mid phase 2

ALX2004 Program

ALX2004
Dose-escalation and expansion
Modality/Target
EGFR ADC
Indication
EGFR-Expressing Solid Tumors
Status
FPI mid-year ’25
mid phase 1
Explore Our Clinical Trials

ALX-sponsored trial

Completed trial

ALX Oncology retains worldwide rights to evorpacept.

  1. Sanofi sponsors SARCLISA® clinical trial.
  2. Lilly supplies CYRAMZA® for ALX Oncology’s ASPEN-06 program
  3. Jazz Pharmaceuticals sponsors zanidatamab clinical trial.